We are analyzing https://link.springer.com/article/10.1007/s40291-017-0259-y.

Title:
Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer | Molecular Diagnosis & Therapy
Description:
Epi proColon® 2.0 CE is a blood-based test designed to aid in the early detection of colorectal cancer. The test comprises a qualitative assay for the polymerase chain reaction (PCR) detection of methylated Septin9 DNA, the presence of which is associated with colorectal cancer: however, positive results should be verified by colonoscopy or sigmoidoscopy. Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with high clinical sensitivity and specificity in pivotal case-control studies. The sensitivity of the test did not appear to be affected by the tumour location or by patient age or gender. In addition, limited data suggest that Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with higher sensitivity and generally similar specificity to that of the faecal immunochemical test, and with higher sensitivity and specificity to that of the guaiac-based faecal occult blood test (statistical data not available). In an observational study, most patients who refused colonoscopy for screening accepted a non-invasive test option as an alternative, and preferred Epi proColon® 2.0 CE over a stool-based test. Large prospective trials of Epi proColon® 2.0 CE in a screening setting will be required to further elucidate the cost-effectiveness of the test. Nevertheless, currently available data suggests that Epi proColon® 2.0 CE has the potential to be a sensitive and convenient screening option for patients refusing screening by colonoscopy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, colorectal, article, pubmed, screening, google, scholar, test, epi, procolon, detection, cas, methylated, dna, epigenomics, bloodbased, septin, sept, plasma, central, content, data, patients, privacy, cookies, european, diagnosis, lamb, assay, colonoscopy, blood, access, plos, chinese, media, information, publish, research, search, yvette, dhillon, sensitivity, immunochemical, methylation, clin, accessed, jan, springer, log, journal,

Topics {✒️}

polymerase chain reaction faecal immunochemical test month download article/chapter blood-based screening test blood-based test designed pivotal case-control studies circulating cell-free dna chinese anti-cancer association early-stage colorectal cancer colorectal cancer screening related subjects sided colon cancers colorectal cancer facts asymptomatic colorectal cancer stool-based test high clinical sensitivity full article pdf methylated septin9 dna stool based tests privacy choices/manage cookies blood-based biomarkers lamb & sohita dhillon detecting colorectal neoplasm colorectal precancerous lesions dna methylation biomarkers chinese screening guideline fecal test offered global cancer statistics convenient screening option invasive test option methylated sept9 dna invasive dna tests check access lofton-day instant access patients refusing screening chinese medical association colorectal cancer reliable screening method chinese society epigenetic markers sept9 article lamb tissue supply crucial components gastrointestinal stromal cancers full supplement publication clinical biochemistry section conditions privacy policy large prospective trials european economic area

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer
         description:Epi proColon® 2.0 CE is a blood-based test designed to aid in the early detection of colorectal cancer. The test comprises a qualitative assay for the polymerase chain reaction (PCR) detection of methylated Septin9 DNA, the presence of which is associated with colorectal cancer: however, positive results should be verified by colonoscopy or sigmoidoscopy. Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with high clinical sensitivity and specificity in pivotal case-control studies. The sensitivity of the test did not appear to be affected by the tumour location or by patient age or gender. In addition, limited data suggest that Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with higher sensitivity and generally similar specificity to that of the faecal immunochemical test, and with higher sensitivity and specificity to that of the guaiac-based faecal occult blood test (statistical data not available). In an observational study, most patients who refused colonoscopy for screening accepted a non-invasive test option as an alternative, and preferred Epi proColon® 2.0 CE over a stool-based test. Large prospective trials of Epi proColon® 2.0 CE in a screening setting will be required to further elucidate the cost-effectiveness of the test. Nevertheless, currently available data suggests that Epi proColon® 2.0 CE has the potential to be a sensitive and convenient screening option for patients refusing screening by colonoscopy.
         datePublished:2017-02-02T00:00:00Z
         dateModified:2017-02-02T00:00:00Z
         pageStart:225
         pageEnd:232
         sameAs:https://doi.org/10.1007/s40291-017-0259-y
         keywords:
            Colorectal Cancer
            Colorectal Cancer Screening
            Faecal Immunochemical Test
            Colorectal Cancer Tissue
            Sensitive Polymerase Chain Reaction
            Molecular Medicine
            Human Genetics
            Cancer Research
            Laboratory Medicine
            Pharmacotherapy
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40291-017-0259-y/MediaObjects/40291_2017_259_Fig1_HTML.gif
         isPartOf:
            name:Molecular Diagnosis & Therapy
            issn:
               1179-2000
               1177-1062
            volumeNumber:21
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yvette N. Lamb
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sohita Dhillon
               affiliation:
                     name:Springer
                     address:
                        name:Springer, Auckland, New Zealand
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer
      description:Epi proColon® 2.0 CE is a blood-based test designed to aid in the early detection of colorectal cancer. The test comprises a qualitative assay for the polymerase chain reaction (PCR) detection of methylated Septin9 DNA, the presence of which is associated with colorectal cancer: however, positive results should be verified by colonoscopy or sigmoidoscopy. Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with high clinical sensitivity and specificity in pivotal case-control studies. The sensitivity of the test did not appear to be affected by the tumour location or by patient age or gender. In addition, limited data suggest that Epi proColon® 2.0 CE discriminated between patients with colorectal cancer and healthy controls with higher sensitivity and generally similar specificity to that of the faecal immunochemical test, and with higher sensitivity and specificity to that of the guaiac-based faecal occult blood test (statistical data not available). In an observational study, most patients who refused colonoscopy for screening accepted a non-invasive test option as an alternative, and preferred Epi proColon® 2.0 CE over a stool-based test. Large prospective trials of Epi proColon® 2.0 CE in a screening setting will be required to further elucidate the cost-effectiveness of the test. Nevertheless, currently available data suggests that Epi proColon® 2.0 CE has the potential to be a sensitive and convenient screening option for patients refusing screening by colonoscopy.
      datePublished:2017-02-02T00:00:00Z
      dateModified:2017-02-02T00:00:00Z
      pageStart:225
      pageEnd:232
      sameAs:https://doi.org/10.1007/s40291-017-0259-y
      keywords:
         Colorectal Cancer
         Colorectal Cancer Screening
         Faecal Immunochemical Test
         Colorectal Cancer Tissue
         Sensitive Polymerase Chain Reaction
         Molecular Medicine
         Human Genetics
         Cancer Research
         Laboratory Medicine
         Pharmacotherapy
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40291-017-0259-y/MediaObjects/40291_2017_259_Fig1_HTML.gif
      isPartOf:
         name:Molecular Diagnosis & Therapy
         issn:
            1179-2000
            1177-1062
         volumeNumber:21
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yvette N. Lamb
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sohita Dhillon
            affiliation:
                  name:Springer
                  address:
                     name:Springer, Auckland, New Zealand
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Molecular Diagnosis & Therapy
      issn:
         1179-2000
         1177-1062
      volumeNumber:21
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
      name:Springer
      address:
         name:Springer, Auckland, New Zealand
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yvette N. Lamb
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sohita Dhillon
      affiliation:
            name:Springer
            address:
               name:Springer, Auckland, New Zealand
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Springer, Auckland, New Zealand
      name:Springer, Auckland, New Zealand
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(99)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.71s.

LINK . SPRINGER . COM {}